We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
-1.98%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$4.46B
AUM Growth
-$732M
Cap. Flow
-$476M
Cap. Flow %
-10.67%
Top 10 Hldgs %
48.58%
Holding
171
New
10
Increased
26
Reduced
81
Closed
23

Top Buys

Rank Stock Value
1
AKRO
Akero Therapeutics
AKRO
+$53M
2
BEAM icon
Beam Therapeutics
BEAM
+$23M
3
SYK icon
Stryker
SYK
+$17.7M
4
ABBV icon
AbbVie
ABBV
+$17.5M
5
BAX icon
Baxter International
BAX
+$14.9M

Top Sells

Rank Stock Value
1
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$204M
2
ARVN icon
Arvinas
ARVN
+$45.8M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$34.7M
4
VRNA
Verona Pharma
VRNA
+$30.4M
5
TNDM icon
Tandem Diabetes Care
TNDM
+$28.2M

Sector Composition

Rank Sector Weight
1 Healthcare 99.87%
2 Technology 0.01%
3 Communication Services 0.01%
4 Consumer Discretionary 0%
5 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARGX icon
1
argenx
ARGX
$53.8B
$343M 7.68%
578,874
-14,310
-2% -$9.03M
IONS icon
2
Ionis Pharmaceuticals
IONS
$8.99B
$237M 5.31%
7,853,198
-15,502
-0.2% -$508K
SYK icon
3
Stryker
SYK
$123B
$211M 4.73%
566,597
+46,571
+9% +$17.7M
ISRG icon
4
Intuitive Surgical
ISRG
$122B
$211M 4.72%
425,746
-38,631
-8% -$21.4M
ALNY icon
5
Alnylam Pharmaceuticals
ALNY
$35.7B
$207M 4.65%
768,147
-2,121
-0.3% -$545K
ABT icon
6
Abbott
ABT
$175B
$206M 4.63%
1,556,129
-132,531
-8% -$16.9M
NBIX icon
7
Neurocrine Biosciences
NBIX
$17.2B
$201M 4.51%
1,820,000
– –
VRTX icon
8
Vertex Pharmaceuticals
VRTX
$123B
$200M 4.49%
413,071
-74,363
-15% -$34.7M
BSX icon
9
Boston Scientific
BSX
$65.4B
$197M 4.41%
1,951,020
-184,275
-9% -$18.6M
RVMD icon
10
Revolution Medicines
RVMD
$39.6B
$155M 3.47%
4,374,300
-12,600
-0.3% -$511K
INCY icon
11
Incyte
INCY
$23.4B
$127M 2.84%
2,091,780
-65,698
-3% -$4.58M
AGIO icon
12
Agios Pharmaceuticals
AGIO
$2.36B
$103M 2.31%
3,515,150
– –
UNH icon
13
UnitedHealth
UNH
$387B
$86.3M 1.93%
164,742
+5,029
+3% +$2.57M
MDT icon
14
Medtronic
MDT
$106B
$84.3M 1.89%
938,355
-104,593
-10% -$9.36M
SRRK icon
15
Scholar Rock
SRRK
$6.33B
$80.6M 1.81%
2,506,890
-3,800
-0.2% -$146K
BDX icon
16
Becton Dickinson
BDX
$43.6B
$78.9M 1.77%
344,311
+6,763
+2% +$1.57M
DXCM icon
17
DexCom
DXCM
$29.6B
$72.7M 1.63%
1,064,108
+19,064
+2% +$1.56M
PODD icon
18
Insulet
PODD
$11.4B
$71.2M 1.6%
271,286
-50,631
-16% -$13.7M
EW icon
19
Edwards Lifesciences
EW
$49.4B
$70.4M 1.58%
971,969
-125,879
-11% -$9.01M
CLDX icon
20
Celldex Therapeutics
CLDX
$2.77B
$55.7M 1.25%
3,071,615
– –
PEN icon
21
Penumbra
PEN
$12.5B
$54.7M 1.23%
204,517
-33,536
-14% -$9.07M
AKRO
22
DELISTED
Akero Therapeutics
AKRO
$50.6M 1.13%
+1,250,666
New +$53M
BHVN icon
23
Biohaven
BHVN
$2.32B
$49.1M 1.1%
2,040,853
– –
BEAM icon
24
Beam Therapeutics
BEAM
$2.83B
$46.8M 1.05%
2,395,930
+877,809
+58% +$23M
MRNA icon
25
Moderna
MRNA
$24.5B
$43M 0.96%
1,518,122
-82,755
-5% -$2.94M
1
2 3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q1 2025 Portfolio in Review

As of Q1 2025, Bellevue Group held 171 positions worth $4.46B, down 14% from $5.2B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Bellevue Group withdrew a net $476M in Q1 2025, closing 23 positions and reducing 81 holdings. Its most notable exit was Intra-Cellular Therapies Inc., an estimated $204M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Technology and Communication Services.

Against the trend, Bellevue Group opened a new position in Akero Therapeutics worth $50.6M.

  • Bellevue Group's largest Q1 2025 buy was Akero Therapeutics: 1,250,666 shares worth $50.6M.
  • Bellevue Group added most to Beam Therapeutics in Q1 2025, an estimated $23M increase.
  • Bellevue Group's biggest Q1 2025 reduction was Vertex Pharmaceuticals, cutting an estimated $34.7M.
  • Bellevue Group fully exited Intra-Cellular Therapies Inc. in Q1 2025, selling an estimated $204M.
  • Bellevue Group's ten largest holdings make up 49% of its $4.46B portfolio in Q1 2025.
  • Bellevue Group opened 10 new positions and closed 23 in Q1 2025.
  • Bellevue Group's portfolio value fell 14% quarter-over-quarter to $4.46B.

Based on Bellevue Group's 13F filing for Q1 2025, filed 14 May 2025.